Lumera Announces Exclusive Licensing Agreement to Capitalize on Growing Commercial Nano-Based Biochip Market

Jan 25, 2005, 00:00 ET from Lumera Corp.

    BOTHELL, Wash., Jan. 25 /PRNewswire-FirstCall/ -- Lumera Corp.
 (Nasdaq:   LMRA) announced it has acquired the exclusive rights to Helix
 Biopharma's (HBP.TO) Heterodimer Protein Technology (HPT).  The technology
 moves Lumera closer to launching a unique product set aimed to capitalize on
 the multi-billion dollar proteomic array market.
     "When combined with Lumera's existing NanoCapture(TM) Array (NCA)
 technology, the HPT surface chemistry allows us to bring a new level of value
 to researchers and scientists concerned with protein research," said Lumera
 Chief Executive Officer Tom Mino.  "The acquisition of this technology
 showcases Lumera's core competency of bringing important intellectual property
 to the commercial marketplace, and in this instance, could revolutionize the
 biochip industry by making protein arrays a reality."
     The combination of the Helix HPT technology and Lumera's proprietary
 nanosurface modification chemistry will, for the first time, allow researchers
 to consistently take existing DNA arrays to produce protein arrays that
 accurately mimic the native living cell environment of the body.
     This capability could have a significant impact on the diagnostic
 capabilities of researchers.  By enabling researchers to evaluate, with more
 clarity and accuracy, the impact of various proteins on living cells there may
 be significant time and cost improvements to many important elements of
 commercial research including drug screening and toxicology testing.
     "We can now produce and capture proteins on a silicon chip surface while
 keeping proteins fully functional," said Lumera Chief Technology Officer
 Robert Petcavich.  "Combining HPT selective capture chemistry with our chip
 manufacturing and surface chemistries provides a biologically compatible
 surface perfectly suited for printing DNA or proteins.  Already, we have
 produced prototype NCA's and carried out enzymatic, binding and proteomic
 studies with outstanding results."
     Lumera will target drug screening, toxicity, protein-protein interaction
 pathways and selected diagnostic applications.  Lumera plans to begin shipping
 product based on the technology in 2005.
     Lumera has become a nanotechnology market leader by developing proprietary
 technologies and by licensing and commercializing technology products based on
 exclusive intellectual property.  Previously, Lumera has announced exclusive
 licensing agreements with the University of Washington and Arizona
     About Lumera
     Lumera is an emerging leader in the field of nanotechnology.  The company
 designs proprietary molecular structures and polymer compounds for a broad
 range of electro-optic, RF and specialty coating applications.  The company
 also has developed proprietary processes for fabricating such devices.  For
 more information, please visit
     Certain statements contained in this release are forward-looking
 statements that involve a number of risks and uncertainties.  Factors that
 could cause actual results to differ materially from those projected in the
 company's forward-looking statements include the following: market acceptance
 of our technologies and products; our ability to obtain financing; our
 financial and technical resources relative to those of our competitors; our
 ability to keep up with rapid technological change; government regulation of
 our technologies; our ability to enforce our intellectual property rights and
 protect our proprietary technologies; the ability to obtain additional
 contract awards and to develop partnership opportunities; the timing of
 commercial product launches; the ability to achieve key technical milestones
 in key products; and other risk factors identified from time to time in the
 company's SEC reports, including in its Annual Report on 10-K for the year
 ended December 31, 2003, and its Quarterly Reports on Form 10-Q.

SOURCE Lumera Corp.